Science Corporation Prepares for Pioneering Human Trials of Brain-Computer Interface

Science Corporation, founded by Max Hodak, former Neuralink president, is set to launch its first U.S. human trials for a biohybrid brain-computer interface. Dr. Murat Günel, head of Yale Medical School's Department of Neurosurgery, has joined as a scientific adviser intending to place the first sensor in a patient's brain. Key Developments:

• Funding and Valuation: Science Corporation secured $230 million in Series C funding, valuing the company at $1.5 billion.
• Innovative Approach: Unlike conventional methods using metal probes, Science's interface involves a biohybrid design integrating lab-grown neurons and electronics, seen as less damaging to the brain.
• Advanced Technology: The company’s PRIMA device for restoring vision in people with blindness has been successfully advanced through clinical trials.
• Human Trials Plan: Initial trials will insert a sensor without embedded neurons under the skull to measure brain activity during necessary surgeries in patients with conditions like strokes.
• Potential Applications: The device could evolve to treat conditions like Parkinson's disease more effectively by combining the biological and electronic systems. Challenges faced: regulatory hurdles, securing FDA approval for trials, and engineering lab-grown neurons for medical use.
• Long-term Vision: Hodak envisions using this technology for human enhancement, including introducing new human senses. Conclusion: As Science Corporation advances its pioneering work, the potential to treat neurological conditions innovatively could mark a significant shift in neurotechnology.